GlassScriptPhysician profile
Andrea C Bryan
NPI 1861579518
$3,873.84
in general payments reported to CMS, 2019-2025
19 companies · $1,059 in 2025
The $1,059 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $129 · 2021: $467 · 2022: $418 · 2023: $991 · 2024: $564 · 2025: $1,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,613.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $960.71 | 2019-2025 | Watchman Flx, Watchman Access System, Bodyguardian |
| Abbott Laboratories | $574.44 | 2022-2025 | Cardiomems, Mitraclip, Triclip |
| Amgen INC. | $432.13 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $392.31 | 2020-2025 | Lifevest |
| Edwards Lifesciences Corporation | $214.67 | 2019-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Novartis Pharmaceuticals Corporation | $198.54 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $191.26 | 2021-2025 | Eliquis, Camzyos |
| Medtronic, INC. | $155.79 | 2025 | Inceptiv |
| Janssen Pharmaceuticals, INC | $126.53 | 2020-2024 | Xarelto |
| Astellas Pharma US INC | $99.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.22 | 2020-2023 | Jardiance |
| Pfizer INC. | $87.69 | 2019-2025 | |
| Abiomed | $82.34 | 2021-2022 | |
| Philips North America LLC | $80.13 | 2023-2025 | (5091) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided |
| Astrazeneca Pharmaceuticals LP | $68.70 | 2020-2023 | Andexxa, Farxiga |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $39.57 | 2023 | Assure Wcd |
| Cardiva Medical, INC. | $36.38 | 2025 | Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Vvcs 6-12f |
| Biosense Webster, INC. | $22.18 | 2019 | |
| Alnylam Pharmaceuticals INC. | $14.25 | 2023 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Bryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.